Drug
Semaglutide
Semaglutide: highest development phase Post-Market, developed by Novo Nordisk. 9 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Novo Nordisk
Trials
| Drug | Phase | Indication |
|---|---|---|
| Semaglutide NCT07900438 | Post-Market | Cardiovascular Risk |
| Semaglutide NCT04916470 | Phase 3 | Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2 |
| Semaglutide NCT03548987 | Phase 3 | Metabolism and Nutrition Disorder |
| Semaglutide NCT04822181 | Phase 3 | Non-alcoholic Steatohepatitis |
| Semaglutide NCT03693430 | Phase 3 | Overweight |
| Semaglutide NCT03842202 | Phase 1 | Overweight |
| semaglutide NCT02773381 | Phase 1 | Diabetes |
| semaglutide NCT00813020 | Phase 1 | Diabetes |
| semaglutide NCT02212067 | Phase 1 | Diabetes |
Latest
No recent events.
Follow Semaglutide on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.